ATE305921T1 - Neue analoga von 16-hydroxyeicosatetraensäure - Google Patents

Neue analoga von 16-hydroxyeicosatetraensäure

Info

Publication number
ATE305921T1
ATE305921T1 AT99924250T AT99924250T ATE305921T1 AT E305921 T1 ATE305921 T1 AT E305921T1 AT 99924250 T AT99924250 T AT 99924250T AT 99924250 T AT99924250 T AT 99924250T AT E305921 T1 ATE305921 T1 AT E305921T1
Authority
AT
Austria
Prior art keywords
hete
hydroxyeicosatetraenic
acid
agonists
new analogue
Prior art date
Application number
AT99924250T
Other languages
English (en)
Inventor
John R Falck
Martin M Bednar
Cordell E Gross
Michael Balazy
Original Assignee
Univ Vermont
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont, Univ Texas filed Critical Univ Vermont
Application granted granted Critical
Publication of ATE305921T1 publication Critical patent/ATE305921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99924250T 1998-05-15 1999-05-14 Neue analoga von 16-hydroxyeicosatetraensäure ATE305921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8560298P 1998-05-15 1998-05-15
PCT/US1999/010728 WO1999059964A1 (en) 1998-05-15 1999-05-14 Novel analogs of 16-hydroxyeicosatetraenoic acid

Publications (1)

Publication Number Publication Date
ATE305921T1 true ATE305921T1 (de) 2005-10-15

Family

ID=22192722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99924250T ATE305921T1 (de) 1998-05-15 1999-05-14 Neue analoga von 16-hydroxyeicosatetraensäure

Country Status (7)

Country Link
US (3) US6359158B1 (de)
EP (1) EP1077936B1 (de)
JP (1) JP2002515480A (de)
AT (1) ATE305921T1 (de)
CA (1) CA2332272A1 (de)
DE (1) DE69927582D1 (de)
WO (1) WO1999059964A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE305921T1 (de) * 1998-05-15 2005-10-15 Univ Vermont Neue analoga von 16-hydroxyeicosatetraensäure
US6320062B1 (en) 1999-11-09 2001-11-20 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
JP3866197B2 (ja) * 2000-09-13 2007-01-10 中外製薬株式会社 虚血性疾患治療剤
MXPA04002336A (es) * 2001-09-14 2005-10-05 Univ Texas Analogos del acido hidroxieicosenoico.
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
AU2003280097A1 (en) * 2002-12-03 2004-06-23 Koninklijke Philips Electronics N.V. A simplified decoder for a bit interleaved cofdm-mimo system
WO2004072013A1 (ja) * 2003-02-14 2004-08-26 Taisho Pharmaceutical Co.,Ltd. ヒドロキシエイコサジエン酸化合物
DE602004021574D1 (de) * 2003-02-26 2009-07-30 Univ Johns Hopkins Modulatorische verbindungen und verfahren für glutamattransport
WO2004080389A2 (en) * 2003-03-07 2004-09-23 Taisho Pharmaceutical Co., Ltd. Hydroxyeicosadienamide compounds
AU2004285473A1 (en) * 2003-10-21 2005-05-12 Johns Hopkins University Neuroprotection with beta-lactam compounds
ATE481968T1 (de) 2004-07-14 2010-10-15 Inflammation Res Ct Company Lt Verfahren zur hemmung von tumormetastasierung
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2015071766A1 (en) 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
US11690825B2 (en) 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
EP3976047A4 (de) * 2019-06-03 2023-07-05 Migal Galilee Research Institute Ltd. 5,6-dihet-lacton zur behandlung von mikrovaskulärer dysfunktion
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111803482B (zh) * 2020-07-31 2021-09-10 中国农业科学院特产研究所 鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164381A (en) 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5256538A (en) 1991-03-08 1993-10-26 Board Of Regents, The University Of Texas System Detection of early platelet activation and prediagnosis of thrombotic events
US5334736A (en) 1991-05-16 1994-08-02 University Of Texas System Board Of Regents Functionalizing carbohydrate derivatives by base-induced β-eliminatiom forming bioactive derivatives containing hydroxy-diene subunits
US5273999A (en) 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
EP0629213B1 (de) 1992-03-07 1996-10-23 Morinaga Milk Industry Co., Ltd. Verwendung eines immunstimulierenden agens
US5324743A (en) 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5527890A (en) 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5612377A (en) 1994-08-04 1997-03-18 Minnesota Mining And Manufacturing Company Method of inhibiting leukotriene biosynthesis
US5753702A (en) 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
ATE305921T1 (de) * 1998-05-15 2005-10-15 Univ Vermont Neue analoga von 16-hydroxyeicosatetraensäure
MXPA04002336A (es) 2001-09-14 2005-10-05 Univ Texas Analogos del acido hidroxieicosenoico.

Also Published As

Publication number Publication date
JP2002515480A (ja) 2002-05-28
US6359158B1 (en) 2002-03-19
EP1077936B1 (de) 2005-10-05
CA2332272A1 (en) 1999-11-25
US6562988B2 (en) 2003-05-13
US20020165262A1 (en) 2002-11-07
US6903135B2 (en) 2005-06-07
DE69927582D1 (de) 2006-02-16
WO1999059964A1 (en) 1999-11-25
EP1077936A1 (de) 2001-02-28
US20030176509A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
ATE305921T1 (de) Neue analoga von 16-hydroxyeicosatetraensäure
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
HUP0300582A2 (hu) Gyógyszerkészítmények
EA200000718A1 (ru) Композиции целекоксиба
NO20025450D0 (no) Ny farmasöytisk sammensetning
EA200100872A1 (ru) Композиция валдекоксиба
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
IT1282352B1 (it) Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
DE69507614D1 (de) 3-amino-2-oxo-piperidinessigsäurederivate, die eine argininnachahmende verbindung, mit enzyminhibitorischen wirkung enthalten
YU7797A (sh) Kombinovana terapija za osteoporozu
IL140930A0 (en) Compounds and compositions for delivering active agents
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
PL367094A1 (en) Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
SE0102055D0 (sv) New Compounds
EP1254668A3 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines GABA-A alpha 2/3 Agonisten zur Verwendung in Angstzuständen und Depressionen
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
EE04868B1 (et) Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties